Exploring Key Insights of the Acquired Immunodeficiency Syndrome (AIDS) Market: Growth Prospects, Emerging Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Rapidly is the Acquired Immunodeficiency Syndrome (AIDS) Market Expected to Expand Between 2025 and 2034 Based on Current Trends?
The market for acquired immunodeficiency syndrome (AIDS) has seen robust growth in the recent past. There’s an expected growth from $32.09 billion in 2024 to $33.85 billion in 2025, with a compound annual growth rate (CAGR) of 5.5%. The growth in the previous years has been fueled by an upsurge in HIV infection rates, enhanced government funding in HIV treatment, augmented global awareness campaigns, better diagnostic proficiency, and amplified backing from non-governmental organizations.
A significant increase is anticipated in the market size of acquired immunodeficiency syndrome (AIDS) in the forthcoming years, with a projection of reaching $41.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The escalation in this forecast period is influenced by multiple factors, including the rising demand for long-lasting injectable therapies, the uptick in acceptance of pre-exposure prophylaxis (PrEP), amplified investment in research for HIV cure, the broadening of telemedicine services for HIV care, an emphasis on personalized medicine, and heightened awareness around early HIV diagnosis. In this projected period, major trends involve a shift toward single-tablet regimens, a growing penchant for injectable and implantable HIV treatments, an increasing need for digital health solutions in managing HIV, burgeoning interest in functional HIV cure tactics, and the escalating involvement of artificial intelligence in drug discovery.
How Are the key drivers Contributing to the Expansion of the Acquired Immunodeficiency Syndrome (AIDS) Market?
The rise in HIV infection cases is anticipated to fuel the growth trajectory of the acquired immunodeficiency syndrome (AIDS) market. HIV infections are caused by the human immunodeficiency virus (HIV) that compromises the immune system’s functionality, thereby diminishing the body’s capacity to ward off infections and diseases. Unprotected sex with someone infected, needle or syringe sharing, receiving infected blood products, having several sexual partners, and having a compromised immune system or pre-existing sexually transmitted infections contribute to the upsurge in HIV infection rates. Efficient administration of acquired immunodeficiency syndrome (AIDS) enhances the life expectancy of people infected with HIV. It supports early detection, extends access to effective antiretroviral therapies, improves prevention strategies, and fortifies healthcare systems – all feeding into better containment of the virus. For example, data from the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, showed that in November 2024, there were 112,883 new HIV diagnoses in 2023 across 47 out of 53 countries in Europe, with 24,731 cases documented in the European Union/European Economic Area (EU/EEA). The total crude rate of HIV diagnoses was 12.7 per 100,000 population, marking a 2.4% growth from the 12.4 per 100,000 rate seen in 2022. Consequently, the escalating rates of HIV infections are propelling the acquired immunodeficiency syndrome (AIDS) market.
Get Your Free Sample of the Global Acquired Immunodeficiency Syndrome (AIDS) Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp
Which key players are shaping the future of the Acquired Immunodeficiency Syndrome (AIDS) market?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare
How Are the Latest Trends Influencing the Growth of the Acquired Immunodeficiency Syndrome (AIDS) Market?
Leading businesses in the acquired immunodeficiency syndrome (AIDS) market are concentrating their efforts on the creation of innovative therapies such as long-acting injectables. These therapies are aimed at enhancing patient adherence, decreasing the regularity of dosage, and providing a favorable option to daily oral antiretroviral treatments. Administered through injections, long-acting injectables are slow-releasing medications designed to maintain a level of the active ingredient for extended periods, therefore, minimizing the frequency of dosage when compared to conventional oral medications. For example, in January 2025, GSK plc., a UK-centric pharmaceutical firm, received approval from the European Commission for a long-acting injectable treatment called Vocabria (cabotegravir) plus Rekambys (rilpivirine). This injectable treatment, given via intramuscular injection every one or two months based on the specific treatment plan, is approved for adolescents aged 12 years and older who have HIV. The slow-release feature of these injections could potentially enhance adherence rates among adolescents who find daily pill-based therapies challenging.
Get Instant Access to the Global Acquired Immunodeficiency Syndrome (AIDS) Market Report with Swift Delivery!
What Are the Major Segments of the Acquired Immunodeficiency Syndrome (AIDS) Market and Their Role in Driving Growth?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
What Regions Are At the Forefront of Acquired Immunodeficiency Syndrome (AIDS) Market Expansion?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can We Define the Acquired Immunodeficiency Syndrome (AIDS) Market and Its Key Components?
Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV), which progressively weakens the immune system by destroying CD4 T cells, leaving the body vulnerable to opportunistic infections, severe illnesses, and certain cancers in the absence of effective antiretroviral treatment. It is managed by a combination of antiretroviral therapy (ART), regular monitoring of immune function, prevention of opportunistic infections, and comprehensive healthcare support to improve patient outcomes and quality of life.
Browse Through More Similar Reports By The Business Research Company:
Pneumococcal Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report
Vaccine Contract Manufacturing Global Market Report 2025
Cold Pain Therapy Global Market Report 2025
https://thebusinessresearchcompany.com/report/cold-pain-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
